Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD

Zevenbergen Capital Investments LLC acquired a new stake in Insulet Corporation (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 113,083 shares of the medical instruments supplier’s stock, valued at approximately $32,143,000. Zevenbergen Capital Investments LLC owned approximately 0.16% of Insulet at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Norges Bank bought a new position in Insulet in the second quarter valued at approximately $324,689,000. Qube Research & Technologies Ltd bought a new stake in shares of Insulet during the 2nd quarter worth approximately $131,439,000. Worldquant Millennium Advisors LLC acquired a new stake in shares of Insulet in the 2nd quarter valued at approximately $80,082,000. Squarepoint Ops LLC grew its stake in shares of Insulet by 11,905.8% in the third quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after buying an additional 225,377 shares in the last quarter. Finally, Munro Partners grew its stake in shares of Insulet by 1,483.0% in the third quarter. Munro Partners now owns 227,240 shares of the medical instruments supplier’s stock valued at $70,156,000 after buying an additional 212,885 shares in the last quarter.

Insulet Price Performance

Shares of PODD opened at $208.01 on Tuesday. The company’s 50-day moving average is $244.14 and its 200-day moving average is $287.40. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. The firm has a market capitalization of $14.64 billion, a PE ratio of 59.43, a PEG ratio of 1.25 and a beta of 1.42. Insulet Corporation has a fifty-two week low of $205.11 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. Insulet’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.15 EPS. Equities analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insider Activity

In other news, Director Michael R. Minogue bought 2,030 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.39% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

PODD has been the topic of several analyst reports. Raymond James Financial dropped their price target on shares of Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. TD Cowen lowered shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price objective on the stock. in a research note on Monday, January 26th. The Goldman Sachs Group cut their target price on shares of Insulet from $363.00 to $326.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Oppenheimer reduced their price target on Insulet from $365.00 to $300.00 and set an “outperform” rating for the company in a report on Thursday, February 19th. Finally, Sanford C. Bernstein lowered their price target on Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Twenty equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average price target of $354.24.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.